Aptevo Therapeutics Reports Special Meeting Vote Results

What Happened Aptevo Therapeutics Inc. filed an 8-K on September 23, 2026 reporting the results of its Special Meeting of Stockholders held on September 22, 2026 (proxy statement filed August 31, 2026). Stockholders approved the issuance of more than 20% of the Company's outstanding common stock under the warrant reload and private placement transactions (Nasdaq Rule 5635(d)) and approved the Fifth Amended and Restated 2018 Stock Incentive Plan. A proposed amendment to the Company’s Amended and Restated Certificate of Incorporation (technical/administrative changes) was not approved. The meeting also approved authorization to adjourn if needed.

Key Details

• Proposal 1 (charter amendment): FOR 654,005 / AGAINST 93,851 / ABSTAIN 4,759 / Broker non‑votes 0 — not approved.
• Proposal 2 (issuance >20% under Nasdaq Rule 5635(d)): FOR 319,306 / AGAINST 100,098 / ABSTAIN 4,225 / Broker non‑votes 328,986 — approved.
• Proposal 3 (Fifth Amended and Restated 2018 Stock Incentive Plan): FOR 331,590 / AGAINST 82,399 / ABSTAIN 9,640 / Broker non‑votes 328,986 — approved.
• Proposal 4 (authorization to adjourn): FOR 639,823 / AGAINST 92,829 / ABSTAIN 19,963 / Broker non‑votes 0 — approved.

Why It Matters These votes allow Aptevo to proceed with the planned warrant reload and private placement issuances that together exceed 20% of outstanding common stock as of August 12, 2026, and implement the updated stock incentive plan for employee/participant awards. For investors, the approved issuance and the stock plan are material because they affect share count and potential dilution; the failed charter amendment means the proposed technical and administrative charter changes will not take effect. The proxy and vote totals (including sizable broker non‑votes on the issuance and plan proposals) provide transparency on shareholder support for these governance and financing actions.